ClinicalTrials.Veeva

Menu

Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

Abramson Cancer Center at Penn Medicine logo

Abramson Cancer Center at Penn Medicine

Status

Withdrawn

Conditions

Refractory Malignant Ascites

Treatments

Device: Tunneled Intraperitoneal Drain (IPD)
Procedure: Paracentesis
Device: Peritoneal-Venous shunts (PVS)

Study type

Observational

Funder types

Other

Identifiers

NCT02477657
UPCC 26813

Details and patient eligibility

About

Malignant ascites leads to significant morbidity in patients with terminal cancer. Paracentesis can provide relief, but repeat hospital visits, pain, and short duration of relief after paracentesis are detrimental to quality of life(QOL). Two devices are available as alternatives to paracentesis. The impact of either device on QOL has not fully been explored. A pilot nonrandomized trial measuring palliative care QOL and ascites symptom relief using validated survey instruments is proposed.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Refractory malignant ascites defined as ascites requiring more than one paracentesis to control patient symptoms despite medical therapy with diuretics and a. peritoneal fluid with cytology positive for malignant cells OR
  • Known malignancy with imaging findings of peritoneal carcinomatosis .
  • Eastern Cooperative Oncology Group (ECOG) performance score 3
  • Age greater than or equal to 18
  • Capable of giving informed consent

Exclusion criteria

  • Life expectancy less than one month
  • Coagulopathy defined as international normalized ration (INR) >2 which cannot be corrected with fresh frozen plasma
  • Platelet count <50,000/microliter, which cannot be corrected with platelet transfusion
  • Active skin infections at sites where PVS would be inserted
  • Presence of infectious peritonitis or bacteremia
  • Neutropenia
  • American Heart Association Class D congestive heart failure (ie New York Heart Association Class IV)
  • Stage 5 CKD (ie GFR < 15 mL/min)
  • Severe hypoalbuminemia defined as < 2.2 g/dL
  • Loculated or hemorrhagic ascites
  • History of bleeding gastroesophageal varices
  • Inability to provide informed consent
  • Unable to participate in neuropsychological tests / questionnaires
  • Pregnant or nursing women
  • Anasarca

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems